TIDMDEST
Destiny Pharma PLC
19 October 2018
Destiny Pharma plc
("Destiny Pharma" or the "Company")
BIA celebrates UK bioscience in creating innovative new drugs
and treatment for patients
A series of videos and explainer documents launched, focusing on
cutting-edge R&D taking place in UK biotech companies,
including Destiny Pharma
Destiny Pharma has been chosen to exemplify the UK's leading
status in antimicrobial resistance research
Brighton, United Kingdom - 19 October 2018 - Destiny Pharma
(AIM: DEST), a clinical stage biotechnology company focused on the
development of novel anti-microbial drugs, which address the global
problem of anti-microbial resistance (AMR), notes the launch of a
series of videos and explainer documents from the UK BioIndustry
Association (BIA) celebrating UK bioscience and revealing the
cutting-edge R&D taking place in biotech companies around the
UK.
Destiny Pharma has been chosen, alongside selected other UK
biotech companies, to exemplify the UK's leading status in key
areas of biotechnology including antimicrobial resistance,
genomics, cell and gene therapy and engineering biology. These
videos and explainers cover strategic technologies being developed
to offer potentially life-changing solutions to individuals and
societies across the globe. The materials are available on the
strategic technologies section of the BIA website.
Dr William Love, Chief Scientific Officer and Founder of Destiny
Pharma, commented:
"We welcome the BIA's continued support for companies investing
in the development of much needed novel anti-infective treatments.
The UK is one of the global leaders in antimicrobial resistance
research and these materials give a true sense of the
ground-breaking work being done here. Destiny Pharma is
well-positioned to address in part this global issue through the
continued clinical development of our novel XF drug platform."
The full text of the BIA announcement is reproduced below:
BIA launches videos and explainer documents celebrating UK
bioscience and revealing the cutting-edge R&D taking place in
biotech companies around the UK
The UK BioIndustry Association (BIA) has today launched a series
of four explainer booklets and five videos that celebrate the
fantastic work taking place in UK bioscience companies to create
innovative new drugs and treatments for patients.
The videos and explainers cover key areas of biotechnology
including genomics, cell and gene therapy, antimicrobial resistance
and engineering biology, as well as a video with the BIA charity of
the year Parkinson's UK looking at how artificial intelligence can
help boost R&D into Parkinson's.
All of the materials will be made available at the UK Bioscience
Forum on Thursday 18 October, which brings together stakeholders
from across the UK bioscience ecosystem for a day of panel
discussions, networking and presentations. The keynote speaker for
the event is Sir Mark Walport who will be updating attendees on how
UK Research and Innovation (UKRI) will support the life sciences
sector in the future.
BIA CEO, Steve Bates, said: "UK bioscience companies are at the
forefront of these innovative, converging disciplines and these
materials give a snapshot of the cutting-edge R&D that BIA
member companies are engaged in to bring new treatments to
patients."
"The science profiled in these explainers has the potential to
change the lives of patients living with diseases across the globe.
The vibrancy of the UK bioscience ecosystem continues to attract
top talent and investment from around the world and demonstrates
the ability of our sector to weather political storms."
Case studies and expert opinion for the explainers and videos
came from the BIA's Advisory Committees and working groups. The
BIA's Advisory Committees are crucial mechanisms for highlighting
the most relevant issues facing bioscience companies. Committee
members include influential experts from across the sector.
You can view all of the new materials on the strategic
technologies section of the BIA website.
Notes to editors
Explainer reports: Antimicrobial Resistance, Genomics, Cell and
Gene Therapy, Engineering Biology
Videos: Parkinson's UK & Benevolent AI, Antimicrobial
Resistance, Cell and Gene Therapy, Engineering Biology,
Genomics
Contact: Ed Sexton, Senior Communications Manager, BIA
esexton@bioindustry.org 02076302196
About the BIA
Established over 25 years ago at the infancy of biotechnology,
the BioIndustry Association (BIA) is the trade association for
innovative enterprises involved in UK bioscience. Members include
emerging and more established bioscience companies; pharmaceutical
companies; academic, research and philanthropic organisations; and
service providers to the bioscience sector. The BIA represents the
interests of its members to a broad section of stakeholders, from
government and regulators to patient groups and the media. Our goal
is to secure the UK's position as a global hub and as the best
location for innovative research and commercialisation, enabling
our world-leading research base to deliver healthcare solutions
that can truly make a difference to people's lives.
For further information, please go to www.bioindustry.org and
twitter.com/BIA_UK
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
Simon Sacerdoti, CFO
pressoffice@destinypharma.com
+44 (0)1273 704 440
FTI Consulting
Simon Conway / Victoria Foster Mitchell
destinypharma@fticonsulting.com
+44 (0) 20 3727 1000
Cantor Fitzgerald Europe (Nominated Adviser and Joint
Broker)
Philip Davies / Will Goode, Corporate Finance
Andrew Keith, Healthcare Equity Sales
+44 (0)20 7894 7000
finnCap Ltd (Joint Broker)
Geoff Nash / Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0)20 7220 0500
About Destiny Pharma
Destiny Pharma is an established, clinical stage, innovative
biotechnology company focused on the development of novel medicines
that represent a new approach to the treatment of infectious
disease. These potential new medicines are being developed to
address the need for new drugs for the prevention and treatment of
life-threatening infections caused by antibiotic-resistant
bacteria, often referred to as "superbugs". Tackling anti-microbial
resistance has become a global imperative recognised by the World
Health Organisation (WHO) and the United Nations, as well as the G7
and the G20 countries. For further information, please visit
https://www.destinypharma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAKMMMGVRLGRZM
(END) Dow Jones Newswires
October 19, 2018 02:00 ET (06:00 GMT)
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From Apr 2024 to May 2024
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From May 2023 to May 2024